Healthtech Startup Dozee Plans $10 Mn Debt Raise from Stockhausen

The startup intends to utilize fresh capital for scaling operations, product development, and enhancing its RPM and hospital automation solutions.

Bengaluru-based healthtech startup Dozee is set to secure up to $10 Mn in debt from Singapore’s Stockhausen International through the issuance of optionally convertible debentures (OCDs).

Founded in 2015 by Mudit Dandwate (CEO) and Gaurav Parchani (CTO), Dozee is the brand of Turtle Shell Technologies. It offers contactless remote patient monitoring solutions for hospitals and healthcare providers.

The startup intends to utilize fresh capital for scaling operations, product development, and enhancing its remote patient monitoring (RPM) and hospital automation solutions, which are already being deployed across Indian healthcare facilities.

Second Big Bet from Stockhausen in 2025

The move marks Dozee’s second debt infusion from Stockhausen in 2025, following a March round in which the company raised around ₹71.5 crore (~US $8.3 million) via a mix of equity and debt.

The planned $10 million raise will allow the investor to convert the debt into equity under agreed-upon terms.

While the company has not disclosed an exact closing date or valuation, filings confirm Stockhausen as the sole investor in this tranche.

This follows the March 2025 round, where equity came from C3H, the impact investment arm of Temasek Trust, while Stockhausen provided the debt portion, a deal advised by Touchstone Partners.

According to filings, Dozee closed FY24 with ₹30.5 crore in operating revenue and ₹55.3 crore in net losses, narrowing from the previous year.

From Indian Hospitals to a Global Stage

The startup has raised nearly US $38 million to date from a mix of equity and debt investors, including Prime Venture Partners, 3one4 Capital, YourNest, C3H, and Stockhausen. Notable earlier rounds include a US$6 million Series A in 2021, a US$10 million extension in 2022, and a US$6 million Series A2 in 2023.

With this planned infusion from Stockhausen, Dozee aims to consolidate its position in the RPM segment, compete more aggressively in global markets, and continue reducing operational losses as it scales.

Stay tuned for more such updates on Digital Health News